Skip to content

Study · Randomized controlled trial · n = 226 · 2008

13 results

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K

Diabetes research and clinical practice20 May 2008Cited by 89 (Europe PMC)

PMID18495285 (opens in a new tab)DOI10.1016/j.diabres.2008.03.018 (opens in a new tab)PepBankPUB-18495285
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In Japanese patients with type 2 diabetes, there were no major or minor hypoglycemic events with liraglutide.

    In plain wordsIn Japanese people with type 2 diabetes, no low blood sugar events were reported with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycemic events
    Study

    n = 226

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no major or minor hypoglycemic events.
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide 0.1 mg reduced HbA1c by 0.79% versus placebo.

    In plain wordsIn Japanese people with type 2 diabetes, the lowest liraglutide dose lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1 mg/day · 14 weeksAs given in this study (human).

    Measurements

    HbA1c reduction versus placebo
    0.79%
    liraglutide 0.1 mg

    Source sentences

    Summary
    Liraglutide dose levels reduced HbA(1c) versus placebo (by 0.79%, 1.22%, 1.64% and 1.85%, respectively; p<0.0001 for linear contrast).
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide 0.3 mg reduced HbA1c by 1.22% versus placebo.

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide 0.3 mg lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.3 mg/day · 14 weeksAs given in this study (human).

    Measurements

    HbA1c reduction versus placebo
    1.22%
    liraglutide 0.3 mg

    Source sentences

    Summary
    Liraglutide dose levels reduced HbA(1c) versus placebo (by 0.79%, 1.22%, 1.64% and 1.85%, respectively; p<0.0001 for linear contrast).
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide 0.6 mg reduced HbA1c by 1.64% versus placebo.

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide 0.6 mg lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg/day · 14 weeksAs given in this study (human).

    Measurements

    HbA1c reduction versus placebo
    1.64%
    liraglutide 0.6 mg

    Source sentences

    Summary
    Liraglutide dose levels reduced HbA(1c) versus placebo (by 0.79%, 1.22%, 1.64% and 1.85%, respectively; p<0.0001 for linear contrast).
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide 0.9 mg reduced HbA1c by 1.85% versus placebo.

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide 0.9 mg lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    HbA1c reduction versus placebo
    1.85%
    liraglutide 0.9 mg

    Source sentences

    Summary
    Liraglutide dose levels reduced HbA(1c) versus placebo (by 0.79%, 1.22%, 1.64% and 1.85%, respectively; p<0.0001 for linear contrast).
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, 75% reached HbA1c below 7.0% with liraglutide 0.9 mg/day.

    In plain wordsIn Japanese people with type 2 diabetes, 75% on liraglutide 0.9 mg reached an HbA1c below 7.0%.

    Peptide
    Liraglutide
    Outcome
    Not applicablePatients reaching HbA1c below 7.0%
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    patients with HbA1c < 7.0%
    75%
    liraglutide 0.9 mg

    Source sentences

    Summary
    Liraglutide 0.9mg/day resulted in 75% of patients achieving HbA(1c) <7.0%
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, 57% reached HbA1c below 6.5% with liraglutide 0.9 mg/day.

    In plain wordsIn Japanese people with type 2 diabetes, 57% on liraglutide 0.9 mg reached an HbA1c below 6.5%.

    Peptide
    Liraglutide
    Outcome
    Not applicablePatients reaching HbA1c below 6.5%
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    patients with HbA1c < 6.5%
    57%
    liraglutide 0.9 mg

    Source sentences

    Summary
    and 57% achieving HbA(1c) <6.5%.
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide reduced fasting plasma glucose versus placebo in a dose-response manner, by up to 2.5 mmol/L.

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide lowered fasting blood glucose more than placebo, with larger effects at higher doses.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    fasting plasma glucose reduction
    ≤ 2.5 mmol/L
    versus placebo

    Source sentences

    Summary
    Liraglutide also reduced, with significant dose-response (each p<0.0001 for linear contrast) versus placebo: fasting plasma glucose (up to 2.5mmol/L)
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide reduced the postprandial glucose excursion versus placebo in a dose-response manner, by up to 12.8 mmol/(Lh).

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide reduced the rise in blood glucose after meals more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial (0-3h) glucose excursion
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    postprandial glucose excursion reduction
    ≤ 12.8 mmol/(Lh)
    versus placebo

    Source sentences

    Summary
    postprandial (0-3h) glucose excursion (up to 12.8mmol/(Lh))
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide increased postprandial insulin secretion versus placebo in a dose-response manner, by up to 23.0 microU/(mLh).

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide raised insulin release after meals more than placebo.

    Peptide
    Liraglutide
    Outcome
    IncreasePostprandial insulin secretion
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    postprandial insulin secretion increase
    ≤ 23 microU/(mLh)
    versus placebo

    Source sentences

    Summary
    and increased postprandial insulin secretion (up to 23.0microU/(mLh))
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, liraglutide increased beta-cell function by HOMA-beta versus placebo in a dose-response manner, by up to around 20.0 (microU/mL)/(mg/dL).

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide improved a measure of beta-cell function more than placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell function (HOMA-beta)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Measurements

    HOMA-beta increase
    ≈ 20 (microU/mL)/(mg/dL)
    versus placebo, maximum

    Source sentences

    Summary
    beta-cell function as evaluated by HOMA-beta (up to around 20.0(microU/mL)/(mg/dL)).
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, body weight was unchanged with liraglutide.

    In plain wordsIn Japanese people with type 2 diabetes, body weight did not change with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight was unchanged
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.
  13. 13HumanRandomized controlled trialSafety outcome

    In Japanese patients with type 2 diabetes, no development of liraglutide antibodies was detected.

    In plain wordsIn Japanese people with type 2 diabetes, no antibodies against liraglutide were found.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiraglutide antibodies
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.1, 0.3, 0.6 or 0.9 mg/day · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    no development of liraglutide antibodies was detected.
    1 context sentence
    Summary · context
    Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00154414

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 226Jan 2005 to May 2006

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.